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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
Triptan drugs are safe and effective for use in the prevention of menstrually related
migraines (MRMs).
Study Design: Review of two English language randomized controlled trials and one
pilot randomized control trial
Data Sources: Randomized controlled trials comparing Triptan drugs to a placebo group
were found using Medline, PubMed, and OVID
Outcomes Measured: Incidence of MRM based on patient self-report; number of
relapses; patients’ subjective evaluations of effectiveness based on questionnaire; adverse
effects of Triptan treatment
Results: Two randomized controlled trials and one pilot study were included in this
review. Oral Triptan drugs were shown to be of benefit in the prevention of menstrually
related migraines (MRMs).
Conclusions: The results of the randomized controlled trials reviewed demonstrate that
oral Triptan drugs, given short-term, were safe and effective at preventing menstrually
related migraines (MRMs). However, in one of the RCTs, some migraineurs experienced
post-treatment attacks. There is not a clear explanation for these post-treatment attacks;
further studies need to be conducted to allow for more flexible dosing in order to ensure
that the migraineurs are being treated during their perimenstrual period (PMP).
Additionally, further studies should be conducted comparing Triptan dosing schedules,
dosages, duration of treatment, routes of administration as well as the efficacy of the
drugs within the Triptan class in preventing MRMs.
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Introduction
Menstrually related migraine (MRM) is a common disorder among women
migraineurs. Approximately 60% of women with migraines report an increase in frequency
and/or severity of migraine attacks around the time of their menstrual period.2 The generally
accepted definition of a menstrually related migraine is a migraine that occurs during the
perimenstural period (PMP), which is equated to two days before menses through 2-4 days
of menstruation.2 In MRMs, attacks may occur at other times of the cycle. Attacks that
occur exclusively with menses are reported in 15% of female migraine patients.1 According
to the International Headache Society (IHS), the criteria for diagnosing a menstrual migraine
is that it must occur on days -2 to +3 of menstruation in at least two of three consecutive
cycles.
MRMs are similar to migraine without aura but MRMs tend to be longer in duration,
more intense in severity, less responsive to treatment, and more subject to recurrence after
initial treatment.2 The symptoms of MRMs occur two days before onset of menstruation to
2-4 days during menstruation and are unilateral in location, pulsatile in quality, moderate to
severe in intensity, made worse by physical activity, and associated with nausea,
photophobia, and phonophobia.3
The exact pathophysiology of MRMs is not understood but it is of the general belief
that they are related to the decrease in estrogen levels at menstruation. The trigger of the
MRMs may be related to either the level of estrogen before decline, the rate of decline, or
the magnitude of decline.1
Although there is no recent data, in 2003 there were 10.4 million US physician office
visits for headache.4 “More than 50% of migraine sufferers report a clear relationship
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between migraine attacks and menstrual flow and 10% of patients show migraine
symptomatology exclusively during the PMP.”3 Medical costs of patients with migraine are
estimated to be $2,571/person/year higher than in non-migraine patients.4 The direct cost of
migraine management in the United States is estimated to be $17.7 billion dollars every
year; of this, $1.3 billion represents migraine medical care and $16.5 billion represents
medical costs related to lost of productivity.4 To equate these costs to the percentage of
migraineurs who suffer MRMs, it is estimated that between $1.7 and $8.85 billion is spent
on MRM management. Of this, it is estimated that between 130 million and 650 million
dollars is spent on direct medical care and between 1.65 and 8.25 billion dollars is spent on
loss of productivity due to MRMs.
Three pharmacologic approaches exist for the treatment of MRMs. Short-term
therapy is directed at decreasing both the length and severity of individual migraine attacks.
Long-term preventative therapy taken daily without reference to menstruation is directed at
decreasing attack frequency and severity. Short term preventative therapy is intended to
take before the onset of monthly menstruation.1 Pharmacologic options for MRM
prophylaxis include NSAIDS, ergotamine, dihydroergotamine (DHE), methysergide,
magnesium, beta blockers and calcium channel blockers. Triptans are not only one of the
most frequently used medications in the treatment of acute migraines, but also are the most
effective treatment option. The indication of Triptans for the prevention of MRMs remains
to be seen.
Objective
The objective of this selective EBM review is to determine whether or not Triptan
drugs are safe and effective for use in the prevention of menstrually related migraines
(MRMs).
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Methods
Specific criteria was designated for the selection of the three trials used in this paper.
Criteria for population included women migraineurs aged > 18 years old with MRMs.
Menstrually related migraines were defined as migraines that occur in at least two of three
consecutive cycles on days -2 to +3 of menstruation. The intervention used was
prophylactic oral Triptan drugs. The treatment group receiving a Triptan drug was
compared to the control group receiving a visually matched placebo. Outcomes measured
included the incidence of MRMs based on self-report, number of relapses, patients’
subjective evaluations of effectiveness based on questionnaire, and adverse effects of
Triptan treatment. The types of studies included two RCT (randomized controlled trials)
and a pilot randomized controlled trial.
In Silberstein’s study, patients treated each of their three perimenstrual periods
(PMP) with placebo, Frovatriptan 2.5 mg QD, or Frovatriptan 2.5 mg BID for six days,
beginning two days before anticipated start of MRM. The primary outcome that was
measured in this study was the incidence of HA during these six days.1 The results of this
study were presented as two different subsets of populations. The “ITT” group represented
those patients who took their medication for at least one PMP (perimenstrual period). The
“ITT2” group represented those patients who took all three doses for all three PMPs.
Mannix’s study was comprised of two identically designed, randomized double-blind
parallel group studies. Women received Naratriptan 1 mg BID or a placebo; they took the
study medication three days before their predicted MRM for a total of six days and repeated
this for four consecutive menstrual cycles.2 The primary outcome measured in this study
endpoint was the mean percentage of treated PMPs without MRM, as per patient report.
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Secondary outcomes measured were the percentage of patients who were free of MRM
during all treated PMPs and patient satisfaction. To determine safety of Naratriptan, adverse
events, laboratory tests and vital signs were recorded and analyzed.2
Facchinetti’s study evaluated patients over two menstrual cycles. The patients
received Sumatriptan suppositories (25 mg) to treat attacks in the first cycle and oral
Sumatriptan tablets (50 mg) to treat all attacks in the second cycle.3 The primary outcome
measured was pain relief two hours post-administration. Secondary outcomes of interest in
this study were the number of relapses as well as patients’ appraisal of the study medication
after each treatment period, according to a verbal scale: “ineffective”, “moderately good”,
“good”, “excellent.”3
Data Sources
Keywords used in literature search were “migraine”, “Triptan”, and
“menstruation”. All articles were published in peer reviewed journals in the English
language. Literature searches were conducted via Medline, Pubmed, and OVID. Articles
were selected based on their relevance and on the importance of outcomes to the patient -patient oriented evidence that matters (POEMS). Studies included in the search were
randomized, placebo-controlled, double-blind studies. Studies that were excluded were
those with a patient population under the age of 18 and with a patient population that
included males. Statistics reported in these studies included RRR (relative risk reduction),
ARR (absolute risk reduction), NNT (numbers needed to treat), and p-values.
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Table 1- Demographics and Characteristics of included studies
STUDY

TYPE

# PTS

AGE

INCLUSION CRITERIA

EXCLUSION
W/D
INTERVENTIONS
CRITERIA
>3 non-MRM attacks
Randomized,
per month
double-blind,
18-56 Women migraineurs aged ><15 headache days per
Frovatriptan 2.5 mg QD
placebo18 years with:
month
103 and Frovatriptan 2.5 mg
Silberstein1, 2004 controlled trial 546 Mean age =
migraine headaches
treated with other
BID (both for 6 days)
37.6
according to IHS criteria investigational drugs,
Pregnant and breastfeeding patients
Study 1:
36.1
2 identical, Study 1: (triptan);
More than 6 migraines 20%
randomized,
287
37.7
At least 18 years of age; 1 monthly during either study 1 Naratriptan 1 mg BID
Mannix2, 2007. double-blind,
(placebo) yr H/O migraine as defined of the 2 months before & 10%
for 4 PMPs
placeboStudy 2:
by IHS criteria
screening;
study 2
controlled,
346
Study 2:
Pregnant or
parallel-group
36.7
breastfeeding
studies
(triptan),
36.3
(placebo)
2 groups of women
suffering from migraine
without aura, age range 18Sumatriptan
50, diagnosed according to
Patients on
suppositories (25 mg) for
the criteria in IHS,
prophylactic
all migraine attacks in
Facchinetti3,
71 22-48 (avg
First group: women
medication to prevent
the first cycle &
pilot
study
35.3
+/7.5)
suffering
from
MRM
migraine;
patients
8
Sumatriptan
tablets
2010
Second group: women
taking oral
(50mg) for all attacks in
suffering from OCMM (oral contraceptive for < 3
the second cycle.
contraceptive menstrual
months
migraine)

Outcomes Measured
Outcomes measured were those of patient oriented evidence that matters (POEMs).
Incidence of MRMs was reported via self-report. Patient’s subjective evaluations of overall
effectiveness were measured via questionnaires: “poor”, “fair”, “good”, or “excellent”
(Silberstein); “very” to “somewhat” satisfied, “neutral”, “very” to “somewhat” dissatisfied
(Mannix); “ineffective”, “moderately good”, “good”, “excellent” (Facchinetti).1,2,3 Adverse
events were measured based on patient report.
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Results
In Silberstein’s ITT group, Frovatriptan 2.5 mg QD and 2.5 mg BID were both
superior to placebo in reducing incidence of MRMs. The incidence of MRM with placebo
was 67% (n=325).1 This percentage was reduced to 52% (n=251; p<0.0001) with use of
Frovatriptan 2.4 mg QD and 41% (n=199; p<0.0001) with use of Frovatriptan 2.5 mg BID.1
In ITT2, the percentage of patients with an incidence of MRM was 69% (n=307), 52%
(n=232; p<0.0001), and 43% (n=190; p<0.0001), respectively.1 For both ITT and ITT2, the
QD dosed group represents the experimental event rate (EER) and the placebo dosed group
represents the control event rate (CER).
Both the QD and BID doses reduced the incidence of migraines more effectively
when compared to placebo (p<0.0001). However, the BID dose was rated as more effective
than the QD dose (p<0.0001).1 In the placebo-dosed patients, 66% rated the effectiveness
as either “fair”, “good”, or excellent. This percentage was increased to 80% in the QDdosed patients and 86% in the BID-dosed patients.
It was determined that the incidence and type of adverse events in the intervention
groups were similar to those seen in placebo patients. The incidence of adverse events was
4.1% (BID) and 2.7% (QD) higher than the placebo group . The most common adverse
events were headache, nausea, dizziness, nasopharngitis, dysmenorrhea. Overall, the study
concluded that Frovatriptan, given prophylactically for 6 days, reduced the incidence of
MRMs.1
The results of the two Mannix studies demonstrated, as per patient report, that the
mean percentage of PMPs without MRM was higher in the Naratriptan group compared to
the placebo group in those patients who treated at least one PMP as well as in those patients
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who treated all four PMPs (p<0.05). Of the patients who treated at least one PMP, the
percentage of patients with no MRM in any of the four treated PMP was higher (p=0.006) in
the Naratriptan group than in the placebo group in the second study only. The percentage of
patients with no MRM in at least 50% of PMPs was higher in the Naratriptan group as
compared to the placebo ground in both studies (p<0.05). To summarize these results, the
Mannix trial displayed that Naratriptan prevented MRMs better than placebo.2
At visit two, satisfaction ratings of the efficacy of the study drug were measured via
a patient questionnaire. At this visit, satisfaction in the Naratriptan-treated group was
similar in comparison to the placebo group. However, at visit 5, based on the Cochran
Mantel-Haenszel test, significantly more Naratriptan-treated patients reported greater overall
satisfaction with the medication compared to placebo-treated patients (p<0.05).2
There were no significant adverse events reported in Mannix’s studies. In study one,
the adverse events of the placebo and Naratriptan groups were comparable. In study two,
the incidence of adverse events was slightly higher with Naratriptan as compared to placebotreated patients. The adverse events were paresthesias (drug related), acute pulmonary
edema (not drug-related), and vertigo (drug related), migraines (not drug-related) and
gastritis (drug-related). Overall, Mannix’s study concluded that Naratriptan 1 mg BID for 6
days is effective and generally well tolerated for short term prevention of MRMs.2
The results of Facchinetti’s study demonstrated that the oral formulation of
Sumatriptan was 91% effective. A relapse occurred in 52% of MRM cases when being
treated with Sumatriptan.3
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Table 2. Efficacy of Triptan drugs on preventing MRMs
Study

CER

EER

RRR

ARR

NNT

EER-CER/CER

EER-CER

1/ARR

p-value

Silberstein

0.67

0.41

-0.39

-0.26

4

<0.05

Mannix

0.76

0.60

-0.21

-0.16

6

<0.05

RRR= Relative Risk Reduction; ARR= Absolute Risk Reduction; NNT= Numbers Needed to Treat; CER=
control event rate; EER= experimental event rate

Table 2 displays the treatment effects of the studies. ARR shows the decrease in
amount of MRMs in the Triptan group compared to the placebo group. RRR determines the
effectiveness of Triptan therapy and also the likelihood of another MRM despite Triptan
therapy. NNT determines the number of patients that needed to be treated with Triptan
therapy to prevent a bad outcome (i.e. MRM) from occurring. In Facchinetti’s study, a pvalue was unable to be calculated. Instead, a percent change from baseline was calculated to
determine efficacy. Significant pain relief was reported in 78% of attacks (98/123) treated
with oral Sumatriptan.3
Table 3. Safety of Triptan drugs in preventing MRMs
Study

CER

EER

RRI

ARI

NNH

EER-CER/CER

EER-CER

1/ARI

p-value

Silberstein

0.402

0.443

0.102

0.041

24

p= 0.185

Mannix

0.29

0.33

0.14

0.04

25

NR

RRI= Relative Risk Increase; ARI=Absolute Risk Increase; NNH= numbers needed to harm;
CER= control event rate; EER= experimental event rate
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Table 3 displays the safety of Triptan drugs in the prophylaxis of MRMs. RRI
determines the safety of Triptan therapy and also the likelihood of experiencing an adverse
event during Triptan therapy. ARI shows the increase in amount of adverse events in the
Triptan group compared to the placebo group. NNH was calculated to determine the
number of patients that needed to be treated with Triptan therapy to cause an adverse event;
24-25 patients need to be treated to get one adverse event.
Discussion
The randomized controlled trials used for this study demonstrate that administration
of Triptans during the PMP for the prevention of MRMs is effective in reducing the
incidence of MRMs. The studies did not prove whether or not Triptan drugs were safe for
MRM prophylaxis; the only p-value that was able to be calculated was shown to be
insignificant. However, it can be argued that the benefit of short-term MRM prophylaxis
versus long term chronic prophylaxis is that short-term prophylaxis is not only able to
reduce the amount of time that the body is exposed to medication but also decrease the
amount adverse events.
The three trials that were chosen for this paper studied three different types of
Triptan drugs: Frovatriptan, Sumatriptan, and Naratriptan. Although each of these three
drugs are in the same class, they vary in duration of action, side effect profile, effectiveness
in relation to prevention of MRMs, etc.
Timing of the dosing of the study medication in relation to the anticipated onset of
MRM was seen to be a area of potential imprecision. Since women have differing lengths of
menstrual cycles, it is difficult to determine a fixed PMP that would accurately apply to
every woman. In Mannix’s study, the percentage of patients who reported a post-treatment
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migraine was higher in patients who received Naratriptan compared to the placebo group.2
What remains to be seen is whether the post-treatment migraines were delayed MRMs,
MRMs occurring during PMP due to treatment not covering the entire PMP, or if the posttreatment attacks were simply a non-MRM attack.2
The Facchinetti study looked at Triptan drugs in the acute treatment of MRMs
whereas the other two studies looked at prophylaxis of MRMs with Triptans. The
Silberstein and Mannix studies were interested in the incidence of MRMs as their primary
outcome. Since Facchinetti’s study looked at the treatment of MRMs instead of prophylaxis
of MRMs, it was difficult to find a primary outcome that would parallel with the Silberstein
and Mannix studies. However, prevention of MRM incidence was able to measured by
using “number of relapses” as a marker for incidence of MRMs. The relapse rate used as a
marker for incidence does not delineate between oral and per rectum routes of
administration. Indeed, this represents an area of debate.
Only one patient reported a adverse event that caused a disruption in medication
administration. Adverse events include sensation of chest tightness, a lump in the throat and
tachycardia but the paper does not state which adverse events correlated with the oral-dosed
group and which correlated with the suppository-dosed group. The paper also does not state
which adverse event was due to the medication.3
Additionally, in the Mannix study, “nearly 30% of patients in each study were
receiving daily migraine prophylaxis.”2 Therefore, it is difficult to determine whether the
results of the study were truly due to that treatment regimen itself or to the daily
prophylactic treatment previously taken by the patient.
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Triptans are in the class of 5-HT1 agonists. Serious cardiac events have been seen
with the use of Triptan drugs: coronary artery vasospasm, transient myocardial ischemia,
atrial and ventricular arrhythmias, and myocardial infarction.5 These adverse effects are very
rare. In general, side effects are minor: paresthesias, fatigue, flushing, chest tightness
drowsiness, dizziness, nausea, and sweating.5
Triptans are contraindicated in patients who have a history of CAD, CVA/TIA, PVD,
hemiplegic or basilar migraines, and IBD. Triptans may cause an increase in blood pressure
and thus are contraindicated in patients with hypertension that is uncontrolled. Specifically,
Naratriptan is contraindicated in patients with renal or hepatic dysfunction and Sumatriptan
is contraindicated in patients who have taken a MAO inhibitor two weeks before
administration of Sumatriptan.5
Sumatriptan taken during pregnancy does not appear to increase the risk of birth
defects. There is not enough data to make the same case for other Triptan drugs. Breast
feeding also does not appear to cause any adverse events in the infant. However, the data
that supports this claim is limited.6
Conclusions
Triptans were shown to be effective in the prophylaxis of MRMs. The results of the
trials showed a significant decrease in incidence of MRMs when Triptans were administered
during the PMP. The studies did not prove whether or not Triptan drugs were safe when used in
the prevention of MRMs; only one p-value out of the three studies was calculated and it was
found to be statistically insignificant.
Further studies need to be conducted that compare Triptan dosing schedules, dosages,
duration of treatment, and routes of administration. Further trials are also warranted comparing
drugs within the Triptan class and their efficacy in preventing MRMs.
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